oral glp-1 agonist approved Danuglipron: An GLP-1R Competing with Peptide Injectables for Diabetes and Obesity Wegovy Pill vs. Foundayo: Which
Description
doi: 10.1186/S13063-019-3259-X/FIGURES/2 122 BennettWLBassEBBolenS
Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses
Type 2 diabetes (34.80%) and weight loss (14.71%) emerged as the most predominant indications, while others accounted for 3.92%, and unknown or missing constituted 46.57% (Table 1)
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
F1000Res (2020) 9:F1000 Faculty Rev-239
.webp)
10.1038/nature22378 95 SongS.GuoR.MehmoodA.ZhangL.YinB.YuanC.et al (2022)
